Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug489 | BMS-986337 Wiki | 0.50 |
| drug3127 | Prototype BMS-986165 Wiki | 0.50 |
| drug2138 | Lifestyle medicine Wiki | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug245 | Alcohol Wiki | 0.50 |
| drug3301 | Reference Treatment- BMS-986165-01 Wiki | 0.50 |
| drug490 | BMS-986337 Placebo Wiki | 0.50 |
| drug2461 | N-Acetyl cysteine Wiki | 0.35 |
| drug2176 | Losartan Wiki | 0.17 |
| drug274 | Anakinra Wiki | 0.17 |
| drug1060 | Convalescent plasma Wiki | 0.11 |
| drug3738 | Standard of care Wiki | 0.10 |
Navigate: Correlations HPO
There are 4 clinical trials
A retrospective case series of patients who self-medicated with Famotidine during coronavirus disease 2019 (COVID-19). The study will collect de-identified patient reported outcome measures of patients with confirmed COVID-19 who self-medicated with Famotidine at any dose during the period of illness. Data will be collected by questionnaire and telephone interview. Inclusion criteria: Age>18; Ability to give written informed consent for study participation; Confirmed diagnosis of COVID-19; Use of Famotidine at any dose during period of COVID-19 illness
Description: Symptoms assessed by severity scores on an ordinal scale; 1=not affected to 4= severely affected
Measure: Symptomatic improvement Time: 2 weeksDescription: Oxygen saturation determined by pulse oximetry
Measure: Peripheral blood oxygen saturation Time: 2 weeksThe purpose of this study is to evaluate the drug levels of BMS-986165 in when taken by mouth as various solid tablet prototypes, by healthy participants.
Description: Part A, B, C
Measure: Area under the plasma concentration-time curve from time zero to t (AUC (0-t)) of BMS-986165 Time: Day 1 and Day 7Description: QTcF = Corrected QT interval using the Fridericia formula. QT interval is the time from the start of the Q wave to the end of the T wave.
Measure: Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QTcF Time: Up to approximately 53 days (for Parts A & C), approximately 62 days (for Part B)Description: QRS can be defined as the electrical impulse as it spreads through the ventricles, indicating ventricular depolarization
Measure: Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QRS Time: Up to approximately 53 days (for Parts A & C), approximately 62 days (for Part B)Description: The QT interval is the time from the start of the Q wave to the end of the T wave.
Measure: Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QT interval Time: Up to approximately 53 days (for Parts A & C), approximately 62 days (for Part B)Description: PR interval is the time from the onset of the P wave to the start of the QRS complex
Measure: Incidence of clinically significant changes in electrocardiogram (ECG) parameters: PR interval Time: Up to approximately 53 days (for Parts A & C), approximately 62 days (for Part B)The purpose of this trial is to assess the safety and toxicity profile of the combination of famotidine and oral n-acetyl cysteine in adult outpatients with newly diagnosed SARS-CoV-2 infection.
Description: Data will be collected and entered into Case Report Form in local REDCap sever to include MedDRA Code, Grade and all other data required by NIH per Memorandum, "Guidance for Collection of Adverse Events Related to COVID-19 Infection" dated on 25 March 2020. All data will be reported per this memorandum and in accordance with all applicable Institutional Review Board and FDA requirements.
Measure: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 Time: 0 to 3 monthsThe purpose of this study is to evaluate the safety, tolerability, and drug levels of BMS-986337 in healthy participants and in healthy Japanese participants.
Description: PR interval is the time from the onset of the P wave to the start of the QRS complex
Measure: Number of clinically significant changes in ECG parameters: PR interval Time: Up to 51 daysDescription: QRS can be defined as the electrical impulse as it spreads through the ventricles, indicating ventricular depolarization
Measure: Number of clinically significant changes in ECG parameters: QRS duration Time: Up to 51 daysDescription: QTcF = Corrected QT interval using the Fridericia formula. QT interval is the time from the start of the Q wave to the end of the T wave.
Measure: Number of clinically significant changes in ECG parameters: QTc-interval (Fridericia's) Time: Up to 51 daysDescription: The QT interval is the time from the start of the Q wave to the end of the T wave.
Measure: Number of clinically significant changes in ECG parameters: QT interval Time: Up to 51 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports